Business Wire

RPS Diagnostics Announces Canadian Approval of FebriDx® Test to Help Rapidly Differentiate Viral from Bacterial Acute Respiratory Infection at the Point of Care

SARASOTA, Fla.--(BUSINESS WIRE)--RPS Diagnostics, Inc. (RPS®) today announces that Health Canada issued a Medical Device License for FebriDx® – a rapid, in-office test that uses a fingerstick blood ...
Healio

FDA clears RPS in-office test for dry eye

Please provide your email address to receive an email when new articles are posted on . Rapid Pathogen Screening Inc. announced that the U.S. Food and Drug Administration has approved InflammaDry, a ...
Medscape

FDA Approvals: RPS Adeno Detector, Elecsys NT-proBNP Test, TBA Assay

Jan. 6, 2006 — The US Food and Drug Administration (FDA) approved in 2005 a rapid point-of-care test for adenovirus in tear fluid as an aid in the differential diagnosis of acute conjunctivitis; a new ...
The Business Journals

Sarasota firm gets OK for European sales of new test for respiratory infections

RPS Diagnostic's new FebriDx test uses a finger-stick blood sample to identify and differentiate an immune response to viral and/or bacterial acute febrile respiratory infection. RPS Diagnostics Inc.
PR Newswire

RPS Announces CE Mark of Rapid, Point-Of-Care Test to Help Detect the Body's Immune Response to Viral And Bacterial Infections - FebriDx™

FebriDx is a rapid, disposable, in-office test that helps identify and differentiate a clinically significant immune response to viral and/or bacterial acute febrile respiratory infection at the point ...
Sarasota Herald-Tribune

2nd US study supports local firm RPS' diagnostic test

LAKEWOOD RANCH — Biotech company RPS Diagnostics announced Monday the publication of second U.S. clinical study that supports the accuracy of its 10-minute diagnostic test to identify acute bacterial ...